Glen Kristiansen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9168040/publications.pdf

Version: 2024-02-01

209 papers 7,238 citations

43 h-index 71 g-index

216 all docs

216 docs citations

216 times ranked

10803 citing authors

#	Article	IF	Citations
1	Bi-allelic loss-of-function variants in <i>KIF21A</i> cause severe fetal akinesia with arthrogryposis multiplex. Journal of Medical Genetics, 2023, 60, 48-56.	3.2	26
2	Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2417-2424.	2.5	5
3	The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas. Molecular Oncology, 2022, 16, 982-1008.	4.6	10
4	The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients. Gastroenterology, 2022, 162, 907-919.e10.	1.3	27
5	A randomized trial of riskâ€adapted screening for prostate cancer in young men—Results of the first screening round of the <scp>PROBASE</scp> trial. International Journal of Cancer, 2022, 150, 1861-1869.	5.1	23
6	Overexpression of Parkin in clear cell renal cell carcinoma decreases tumor aggressiveness by regulating CKS2 levels. International Journal of Oncology, 2022, 60, .	3.3	2
7	Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer. Anticancer Research, 2022, 42, 1367-1376.	1.1	4
8	CD103+ Tissue Resident T-Lymphocytes Accumulate in Lung Metastases and Are Correlated with Poor Prognosis in ccRCC. Cancers, 2022, 14, 1541.	3.7	6
9	Interâ€observer agreement for the histological diagnosis of invasive lobular breast carcinoma. Journal of Pathology: Clinical Research, 2022, 8, 191-205.	3.0	19
10	HGG-21. Oncogenic tyrosine kinase gene fusions in infant-type hemispheric gliomas - comparison of RNA- and DNA-based methods for their reliable detection. Neuro-Oncology, 2022, 24, i65-i65.	1.2	0
11	Comprehensive Analysis of N6-Methyladenosine (m6A) Writers, Erasers, and Readers in Cervical Cancer. International Journal of Molecular Sciences, 2022, 23, 7165.	4.1	6
12	Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. World Journal of Urology, 2021, 39, 65-72.	2.2	2
13	Novel insights into the function of <scp>CD24</scp> : A driving force in cancer. International Journal of Cancer, 2021, 148, 546-559.	5.1	100
14	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). Cancer Immunology, Immunotherapy, 2021, 70, 1781-1788.	4.2	22
15	Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). Journal of Cancer Research and Clinical Oncology, 2021, 147, 235-242.	2.5	9
16	Otoferlin is a prognostic biomarker in patients with clear cell renal cell carcinoma: A systematic expression analysis. International Journal of Urology, 2021, 28, 424-431.	1.0	6
17	Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. Urologia Internationalis, 2021, 105, 169-180.	1.3	37
18	Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II – Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy. Urologia Internationalis, 2021, 105, 181-191.	1.3	19

#	Article	IF	CITATIONS
19	miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells. Cancers, 2021, 13, 964.	3.7	5
20	Cardiac Myeloid Sarcoma: Multimodal Imaging and Histopathologic Findings. Radiology: Cardiothoracic Imaging, 2021, 3, e200540.	2.5	1
21	Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). Journal of Cancer Research and Clinical Oncology, 2021, 147, 1273-1274.	2.5	0
22	Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer. Apmis, 2021, 129, 204-212.	2.0	16
23	Tumor Infiltrating Neutrophils Are Frequently Found in Adenocarcinomas of the Biliary Tract and Their Precursor Lesions with Possible Impact on Prognosis. Journal of Personalized Medicine, 2021, 11, 233.	2.5	4
24	DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer. American Journal of Pathology, 2021, 191, 618-630.	3.8	7
25	CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma. Cancers, 2021, 13, 2177.	3.7	18
26	Systematic expression analysis of m 6 A RNA methyltransferases in clear cell renal cell carcinoma. BJUI Compass, 2021, 2, 402-411.	1.3	8
27	No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany. BMC Cancer, 2021, 21, 526.	2.6	3
28	Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours. Nuklearmedizin - NuclearMedicine, 2021, 60, 344-354.	0.7	13
29	Extrahepatic Surgery in Cirrhosis Significantly Increases Portal Pressure in Preclinical Animal Models. Frontiers in Physiology, 2021, 12, 720898.	2.8	7
30	A Combined TLR7/TLR9/GATA3 Score Can Predict Prognosis in Biliary Tract Cancer. Diagnostics, 2021, 11, 1597.	2.6	1
31	Myoglobin, expressed in brown adipose tissue of mice, regulates the content and activity of mitochondria and lipid droplets. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 159026.	2.4	14
32	Application of Computer Generated Images to train Pattern Recognition used in semiquantitative Immunohistochemistry Scoring. Apmis, 2021, , .	2.0	0
33	Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials. Cancers, 2021, 13, 6007.	3.7	6
34	Increased IgG4â€positive plasma cells in nodularâ€sclerosing Hodgkin lymphoma: a diagnostic pitfall. Histopathology, 2020, 76, 244-250.	2.9	12
35	Integrative clinical transcriptome analysis reveals <i>TMPRSS2â€ERG</i> dependency of prognostic biomarkers in prostate adenocarcinoma. International Journal of Cancer, 2020, 146, 2036-2046.	5.1	13
36	Unique and redundant roles of SOX2 and SOX17 in regulating the germ cell tumor fate. International Journal of Cancer, 2020, 146, 1592-1605.	5.1	28

#	Article	IF	CITATIONS
37	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncology, The, 2020, 21, 222-232.	10.7	364
38	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology, 2020, 52, 192-196.	0.6	29
39	Comprehensive Analysis of the ATP-binding Cassette Subfamily B Across Renal Cancers Identifies ABCB8 Overexpression in Phenotypically Aggressive Clear Cell Renal Cell Carcinoma. European Urology Focus, 2020, 7, 1121-1129.	3.1	6
40	Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 736.e1-736.e10.	1.6	2
41	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ TÂCells. Immunity, 2020, 53, 805-823.e15.	14.3	79
42	Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy. Frontiers in Oncology, 2020, 10, 1775.	2.8	24
43	High-accuracy prostate cancer pathology using deep learning. Nature Machine Intelligence, 2020, 2, 411-418.	16.0	89
44	Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis. Translational Andrology and Urology, 2020, 9, 1314-1322.	1.4	10
45	Downstream Neighbor of SON (DONSON) Expression Is Enhanced in Phenotypically Aggressive Prostate Cancers. Cancers, 2020, 12, 3439.	3.7	7
46	Mitophagy-associated genes PINK1 and PARK2 are independent prognostic markers of survival in papillary renal cell carcinoma and associated with aggressive tumor behavior. Scientific Reports, 2020, 10, 18857.	3.3	5
47	Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. EBioMedicine, 2020, 59, 102962.	6.1	31
48	Hereditary Diffuse Gastric Cancer: A Comparative Cohort Study According to Pathogenic Variant Status. Cancers, 2020, 12, 3726.	3.7	9
49	Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma. Translational Oncology, 2020, 13, 100844.	3.7	8
50	Detection of AR-V7 in primary prostate cancer. Cancer Treatment and Research Communications, 2020, 28, 100230.	1.7	0
51	Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood. Journal of Molecular Diagnostics, 2020, 22, 920-933.	2.8	15
52	Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats. International Journal of Molecular Sciences, 2020, 21, 3308.	4.1	7
53	The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 687.e1-687.e11.	1.6	4
54	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. American Journal of Surgical Pathology, 2020, 44, e15-e29.	3.7	40

#	Article	IF	CITATIONS
55	Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer. American Journal of Surgical Pathology, 2020, 44, e30-e46.	3.7	38
56	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. American Journal of Surgical Pathology, 2020, 44, e66-e79.	3.7	26
57	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. American Journal of Surgical Pathology, 2020, 44, e47-e65.	3.7	68
58	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers V. American Journal of Surgical Pathology, 2020, 44, e80-e86.	3.7	17
59	Knockdown of Myoferlin Suppresses Migration and Invasion in Clear-Cell Renal-Cell Carcinoma. Anticancer Research, 2020, 40, 3119-3128.	1.1	4
60	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 777-786.	2.8	20
61	Targeting glycolysis with 2-deoxy-d-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2255-2265.	2.5	10
62	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clinical Epigenetics, 2020, 12, 94.	4.1	26
63	Antibody selection influences the detection of AR-V7 in primary prostate cancer. Cancer Treatment and Research Communications, 2020, 24, 100186.	1.7	10
64	The International Society of Urological Pathology Consultation on Molecular Pathology of Urogenital Cancer. American Journal of Surgical Pathology, 2020, 44, 859-861.	3.7	2
65	Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine, 2020, 52, 102647.	6.1	38
66	The <i>N</i> ⁶ â€methyladenosine (m ⁶ A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesityâ€associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma. BJU International, 2020, 125, 617-624.	2.5	65
67	<i>LAG3</i> (<i>LAG-3</i> , <i>CD223</i>) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma., 2020, 8, e000552.		70
68	Comparative genomic profiling of glandular bladder tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 445-454.	2.8	22
69	Novel insights into the mixed germ cell-sex cord stromal tumor of the testis: detection of chromosomal aneuploidy and further morphological evidence supporting the neoplastic nature of the germ cell component. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 615-623.	2.8	12
70	The role of myoglobin in epithelial cancers: Insights from transcriptomics. International Journal of Molecular Medicine, 2020, 45, 385-400.	4.0	13
71	CD3 and CD20 immune cell densities in primary tumors, lymph node metastasis, and recurrent disease samples of head and neck squamous cell carcinoma Journal of Clinical Oncology, 2020, 38, 6551-6551.	1.6	1
72	HGG-34. DETECTION OF ONCOGENIC FUSION EVENTS IN SUPRATENTORIAL GLIOBLASTOMAS OF YOUNG CHILDREN. Neuro-Oncology, 2020, 22, iii349-iii350.	1.2	0

#	Article	IF	CITATIONS
73	TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor. Scientific Reports, 2019, 9, 11598.	3.3	10
74	Management of Capsular Contracture in Cases of Silicone Gel Breast Implant Rupture with Use of Pulse Lavage and Open Capsulotomy. Aesthetic Plastic Surgery, 2019, 43, 1173-1185.	0.9	10
75	Classic bladder exstrophy and adenocarcinoma of the bladder: Methylome analysis provide no evidence for underlying disease-mechanisms of this association. Cancer Genetics, 2019, 235-236, 18-20.	0.4	10
76	Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging. Oncotarget, 2019, 10, 4149-4160.	1.8	31
77	Systematic expression analysis of the mitochondrial respiratory chain protein subunits identifiesCOX5Bas a prognostic marker in clear cell renal cell carcinoma. International Journal of Urology, 2019, 26, 910-916.	1.0	10
78	Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. Histopathology, 2019, 75, 865-875.	2.9	35
79	DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature. EBioMedicine, 2019, 48, 341-352.	6.1	22
80	Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a webâ€based survey by the European Network of Uropathology. Histopathology, 2019, 74, 844-852.	2.9	7
81	Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy. Frontiers in Oncology, 2019, 9, 403.	2.8	7
82	Combination of CCl ₄ with alcoholic and metabolic injuries mimics human liver fibrosis. American Journal of Physiology - Renal Physiology, 2019, 317, G182-G194.	3.4	37
83	Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays. Laboratory Investigation, 2019, 99, 1527-1534.	3.7	13
84	Chromosomal gains of 12p and 1q are not associated with inferior outcome of pediatric and adolescent germ cell tumors. Pediatric Blood and Cancer, 2019, 66, e27777.	1.5	2
85	Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 263-277.	2.8	19
86	Cribriform and glomeruloid acinar adenocarcinoma of the prostate—an intratumoural intraductal carcinoma?. Histopathology, 2019, 74, 804-808.	2.9	4
87	Intraductal carcinoma of the prostate: a critical re-appraisal. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 525-534.	2.8	40
88	Apelin and apelin receptor expression in renal cell carcinoma. British Journal of Cancer, 2019, 120, 633-639.	6.4	22
89	High-grade Adenocarcinoma of the Prostate Mimicking Urothelial Carcinoma is Negative for TERT Mutations. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 523-528.	1.2	2
90	A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center. BMC Cancer, 2019, 19, 1024.	2.6	5

#	Article	IF	CITATIONS
91	Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. Clinical Epigenetics, 2019, 11, 161.	4.1	49
92	An overview of translational prostate cancer cohorts for prognostic and predictive studies. Histopathology, 2019, 74, 161-170.	2.9	1
93	Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma. World Journal of Urology, 2019, 37, 1639-1647.	2.2	22
94	Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e167-e175.	1.9	10
95	Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Pathology, 2019, 51, 11-20.	0.6	19
96	Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. Clinical Chemistry, 2019, 65, 559-568.	3.2	17
97	YRNA expression in prostate cancer patients: diagnostic and prognostic implications. World Journal of Urology, 2018, 36, 1073-1078.	2.2	17
98	Detailed analysis of adenosine A2a receptor (<i>ADORA2A</i>) and CD73 (5′-nucleotidase,) Tj ETQq0 0 0 rgBT Oncolmmunology, 2018, 7, e1452579.	/Overlock 4.6	10 Tf 50 46 19
99	<scp>P</scp> athogenic and targetable genetic alterations in 70 urachal adenocarcinomas. International Journal of Cancer, 2018, 143, 1764-1773.	5.1	44
100	Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Research and Treatment, 2018, 169, 447-455.	2.5	41
101	Is highâ€grade prostatic intraepithelial neoplasia (HGPIN) a reliable precursor for prostate carcinoma? Implications for clonal evolution and early detection strategies. Journal of Pathology, 2018, 244, 389-393.	4.5	9
102	Next-generation nuclear morphology to grade solid tumours. Lancet Oncology, The, 2018, 19, 275-277.	10.7	2
103	Utility of Pathology Imagebase for standardisation of prostate cancer grading. Histopathology, 2018, 73, 8-18.	2.9	36
104	Threeâ€dimensional reconstruction of prostate cancer architecture with serial immunohistochemical sections: hallmarks of tumour growth, tumour compartmentalisation, and implications for grading and heterogeneity. Histopathology, 2018, 72, 1051-1059.	2.9	21
105	Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study. British Journal of Cancer, 2018, 118, 1217-1228.	6.4	66
106	Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis. Clinical Colorectal Cancer, 2018, 17, e385-e393.	2.3	10
107	Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nature Medicine, 2018, 24, 463-473.	30.7	120
108	YRNA Expression Profiles are Altered in Clear Cell Renal Cell Carcinoma. European Urology Focus, 2018, 4, 260-266.	3.1	18

#	Article	IF	CITATIONS
109	Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. Journal of Urology, 2018, 199, 370-377.	0.4	71
110	Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology, 2018, 50, 60-73.	0.6	29
111	DNA Methylation Analysis of Free-Circulating DNA in Body Fluids. Methods in Molecular Biology, 2018, 1708, 621-641.	0.9	21
112	5′-tRNA Halves are Dysregulated in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2018, 199, 378-383.	0.4	43
113	<i>PD-L1</i> (<i>CD274</i>) and <i>PD-L2</i> (<i>PDCD1LG2</i>) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas. Oncotarget, 2018, 9, 641-650.	1.8	50
114	tRNA-halves are prognostic biomarkers for patients with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 503.e1-503.e7.	1.6	25
115	Quantification of Liver Fibrosis at T1 and T2 Mapping with Extracellular Volume Fraction MRI: Preclinical Results. Radiology, 2018, 288, 748-754.	7.3	96
116	Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clinical Epigenetics, 2018, 10, 11.	4.1	87
117	Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Human Pathology, 2018, 80, 55-64.	2.0	36
118	The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension. Oncotarget, 2018, 9, 36220-36237.	1.8	20
119	Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology and Laboratory Medicine, 2017, 141, 182-183.	2.5	4
120	<pre><scp>UICC</scp> drops the ball in the 8th edition <scp>TNM</scp> staging of urological cancers. Histopathology, 2017, 71, 5-11.</pre>	2.9	37
121	PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma. Clinical Epigenetics, 2017, 9, 12.	4.1	13
122	CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 185-196.	2.8	71
123	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. Clinical Chemistry, 2017, 63, 1288-1296.	3.2	97
124	The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours <i>in vitro</i> and <i>in vivo</i> Journal of Cellular and Molecular Medicine, 2017, 21, 1300-1314.	3.6	69
125	PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. Journal of Molecular Diagnostics, 2017, 19, 107-114.	2.8	41
126	Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e551-e562.	1.9	23

#	Article	IF	CITATIONS
127	Reply: â€A plea for greater standardization in intraductal carcinoma of the prostate â€"greater standardization requires greater evidence': let's use the available evidence. Histopathology, 2017, 70, 1013-1014.	2.9	3
128	High grade adenocarcinoma in the ectopic prostate accompanied by a low grade adenocarcinoma in the orthotopic prostate: an unusual diagnostic pitfall. Pathology, 2017, 49, 665-668.	0.6	2
129	Pathology Imagebaseâ€"a reference image database for standardization of pathology. Histopathology, 2017, 71, 677-685.	2.9	19
130	Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer. International Journal of Cancer, 2017, 141, 1643-1653.	5.1	21
131	Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma. Translational Oncology, 2017, 10, 661-668.	3.7	48
132	Reporting intraductal carcinoma of the prostate: a plea for greater standardization. Histopathology, 2017, 70, 504-507.	2.9	22
133	Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?. International Journal of Molecular Sciences, 2017, 18, 2023.	4.1	8
134	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 52889-52900.	1.8	82
135	Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA. International Journal of Molecular Sciences, 2017, 18, 1151.	4.1	35
136	YRNA expression predicts survival in bladder cancer patients. BMC Cancer, 2017, 17, 749.	2.6	25
137	Exome sequencing characterizes the somatic mutation spectrum of early serrated lesions in a patient with serrated polyposis syndrome (SPS). Hereditary Cancer in Clinical Practice, 2017, 15, 22.	1.5	6
138	Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients. Clinical Epigenetics, 2017, 9, 125.	4.1	38
139	Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer. Oncotarget, 2017, 8, 9885-9898.	1.8	27
140	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget, 2017, 8, 14719-14735.	1.8	21
141	Adipophilin as prognostic biomarker in clear cell renal cell carcinoma. Oncotarget, 2017, 8, 28672-28682.	1.8	19
142	<i>PDCD1</i> (<i>PD-1</i>) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients. Oncotarget, 2017, 8, 41011-41020.	1.8	38
143	Low BUB1 expression is an adverse prognostic marker in gastric adenocarcinoma. Oncotarget, 2017, 8, 76329-76339.	1.8	34
144	Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression. Oncotarget, 2017, 8, 75076-75086.	1.8	10

#	Article	IF	CITATIONS
145	Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology. Oncotarget, 2017, 8, 92890-92903.	1.8	38
146	Diagnostic accuracy of [99mTc]Tc-Sestamibi in the assessment of thyroid nodules. Oncotarget, 2017, 8, 94681-94691.	1.8	9
147	Tissue Factor Expression Does Not Predict Mortality in Breast Cancer Patients. Anticancer Research, 2017, 37, 3259-3264.	1.1	4
148	<i>CXCL12</i> promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients. Oncotarget, 2016, 7, 53309-53320.	1.8	37
149	<i>PD-L1</i> promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget, 2016, 7, 79943-79955.	1.8	73
150	Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. Journal of Clinical Pathology, 2016, 69, 852-857.	2.0	29
151	SEPT9 and SHOX2 DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas. Clinical Epigenetics, 2016, 8, 100.	4.1	46
152	SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells. Molecular Cancer Research, 2016, 14, 574-585.	3.4	36
153	Promoter methylation of the immune checkpoint receptor <i>PD-1</i> (<i>PDCD1</i>) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncolmmunology, 2016, 5, e1221555.	4.6	43
154	<i>CDO1</i> promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. Epigenetics, 2016, 11, 871-880.	2.7	37
155	Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. American Journal of Human Genetics, 2016, 99, 337-351.	6.2	198
156	The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas. British Journal of Cancer, 2016, 115, 454-464.	6.4	48
157	PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. Clinical Epigenetics, 2016, 8, 104.	4.1	16
158	The translational potential of microRNAs as biofluid markers of urological tumours. Nature Reviews Urology, 2016, 13, 734-752.	3.8	104
159	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	2.9	82
160	Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites. Clinical Epigenetics, 2016, 8, 24.	4.1	31
161	Low-level <i>APC</i> mutational mosaicism is the underlying cause in a substantial fraction of unexplained colorectal adenomatous polyposis cases. Journal of Medical Genetics, 2016, 53, 172-179.	3.2	51
162	TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 345-355.	2.8	39

#	Article	IF	CITATIONS
163	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clinical Cancer Research, 2016, 22, 1969-1977.	7.0	170
164	DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract. PLoS ONE, 2016, 11, e0165769.	2.5	8
165	Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of <i>miR-375</i> in prostate cancer progression. Oncotarget, 2016, 7, 59589-59603.	1.8	38
166	A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment. Oncotarget, 2016, 7, 74931-74946.	1.8	49
167	Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma. Oncotarget, 2016, 7, 86490-86499.	1.8	26
168	Ectopic Myoglobin Expression Is Associated with a Favourable Outcome in Head and Neck Squamous Cell Carcinoma Patients. Anticancer Research, 2016, 36, 6235-6242.	1.1	12
169	Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer. Journal of Pathology Informatics, 2016, 7, 3.	1.7	10
170	Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients. Anticancer Research, 2016, 36, 3961-4.	1.1	16
171	Long-Term Analysis of Ab-2 (Clone SN3b) Immunoreactivity as a Prognostic Factor in Breast Carcinoma. Breast Care, 2015, 10, 273-276.	1.4	0
172	Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. Clinical Endocrinology, 2015, 83, 779-789.	2.4	115
173	Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients. BMC Clinical Pathology, 2015, 15, 19.	1.8	16
174	Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS. BioMed Research International, 2015, 2015, 1-23.	1.9	44
175	BMP Inhibition in Seminomas Initiates Acquisition of Pluripotency via NODAL Signaling Resulting in Reprogramming to an Embryonal Carcinoma. PLoS Genetics, 2015, 11, e1005415.	3.5	54
176	Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer. Pathology, 2015, 47, 629-636.	0.6	22
177	Glutathione Sâ€transferaseâ€pi protein expression in prostate cancer–not always a useful diagnostic tool. Histopathology, 2015, 67, 577-579.	2.9	4
178	Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma. Human Pathology, 2015, 46, 1488-1495.	2.0	22
179	Bisulfite Conversion of DNA from Tissues, Cell Lines, Buffy Coat, FFPE Tissues, Microdissected Cells, Swabs, Sputum, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine. Methods in Molecular Biology, 2015, 1589, 139-159.	0.9	17
180	Effect of Peripheral Artery Sympathetic Denervation on Muscle Microperfusion and Macroperfusion in an Animal Peripheral Artery Disease Model Using Contrast-Enhanced Ultrasound and Doppler Flow Measurement. Journal of Vascular and Interventional Radiology, 2015, 26, 1396-1402.e2.	0.5	1

#	Article	IF	Citations
181	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Modern Pathology, 2015, 28, 612-630.	5. 5	106
182	The Distinct Gene Regulatory Network of Myoglobin in Prostate and Breast Cancer. PLoS ONE, 2015, 10, e0142662.	2.5	29
183	Performance Evaluation of Kits for Bisulfite-Conversion of DNA from Tissues, Cell Lines, FFPE Tissues, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine. PLoS ONE, 2014, 9, e93933.	2.5	110
184	CD57 Expression in Incidental, Clinically Manifest, and Metastatic Carcinoma of the Prostate. BioMed Research International, 2014, 2014, 1-9.	1.9	13
185	Hypoxia-inducible factor-mediated induction of WISP-2 contributes to attenuated progression of breast cancer. Hypoxia (Auckland, N Z), 2014, 2, 23.	1.9	15
186	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. Annals of Diagnostic Pathology, 2014, 18, 333-342.	1.3	41
187	Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clinical Pathology, 2014, 14, 10.	1.8	61
188	Correlation between enhancement characteristics of MR mammography and capillary density of breast lesions. European Journal of Radiology, 2014, 83, 2129-2136.	2.6	6
189	KDM5C Is Overexpressed in Prostate Cancer and Is a Prognostic Marker for Prostate-Specific Antigen-Relapse Following Radical Prostatectomy. American Journal of Pathology, 2014, 184, 2430-2437.	3.8	69
190	Loss of Anterior Gradient-2 expression is an independent prognostic factor in colorectal carcinomas. European Journal of Cancer, 2014, 50, 1722-1730.	2.8	18
191	Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with <i>SLC45A3â€ERG</i> gene rearrangement and an unfavorable clinical course. International Journal of Cancer, 2013, 132, 807-812.	5.1	39
192	Diagnostic and Prognostic Value of SHOX2 and SEPT9 DNA Methylation and Cytology in Benign, Paramalignant and Malignant Pleural Effusions. PLoS ONE, 2013, 8, e84225.	2.5	68
193	Analysis of TET Expression/Activity and 5mC Oxidation during Normal and Malignant Germ Cell Development. PLoS ONE, 2013, 8, e82881.	2.5	80
194	Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology, 2012, 60, 125-141.	2.9	74
195	Endogenous Myoglobin in Breast Cancer Is Hypoxia-inducible by Alternative Transcription and Functions to Impair Mitochondrial Activity. Journal of Biological Chemistry, 2011, 286, 43417-43428.	3.4	43
196	Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Laboratory Investigation, 2010, 90, 1102-1116.	3.7	62
197	Molecular pathology of Invasive Lobular Breast Carcinoma. Breast Disease, 2009, 30, 9-14.	0.8	2
198	Manual Microdissection. Methods in Molecular Biology, 2009, 576, 31-38.	0.9	10

#	Article	IF	CITATIONS
199	Peroxisome Proliferator-Activated Receptor \hat{I}^3 Is Highly Expressed in Pancreatic Cancer and Is Associated With Shorter Overall Survival Times. Clinical Cancer Research, 2006, 12, 6444-6451.	7.0	54
200	Is NF- $\hat{\mathbb{P}}$ B predictive of biochemical recurrence in positive-margin prostate cancer?. Nature Reviews Urology, 2005, 2, 134-135.	1.4	0
201	Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. Journal of Pathology, 2005, 205, 359-376.	4.5	162
202	CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate, 2004, 58, 183-192.	2.3	122
203	ALCAM/CD166 is upâ€regulated in lowâ€grade prostate cancer and progressively lost in highâ€grade lesions. Prostate, 2003, 54, 34-43.	2.3	134
204	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. Journal of Urology, 2003, 169, 361-364.	0.4	53
205	Expression of the Cell Adhesion Molecule CD146/MCAM in Non-Small Cell Lung Cancer. Analytical Cellular Pathology, 2003, 25, 77-81.	2.1	68
206	CD24 expression is a new prognostic marker in breast cancer. Clinical Cancer Research, 2003, 9, 4906-13.	7.0	213
207	CD24 Is Expressed in Ovarian Cancer and Is a New Independent Prognostic Marker of Patient Survival. American Journal of Pathology, 2002, 161, 1215-1221.	3.8	239
208	CD10 Expression in Non-Small Cell Lung Cancer. Analytical Cellular Pathology, 2002, 24, 41-46.	2.1	24
209	Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 ?g/L: Are they useful tools for early detection and screening of prostate cancer?. International Journal of Cancer, 2001, 93, 759-765.	5.1	28